Racial Diversity and Reporting in United States Food and Drug Administration Registration Trials for Thoracic Malignancies from 2006 to 2020.
Cancer Invest
; 41(1): 43-47, 2023 Jan.
Article
en En
| MEDLINE
| ID: mdl-36197034
ABSTRACT
There is significant racial disparity in thoracic malignancies in terms of epidemiology and outcomes. We analyzed race reporting and racial diversity in the registration trials of drugs approved by the FDA for thoracic malignancies from 2006 to 2020. We found a significant under-representation of non-white participants in FDA drug registration trials in thoracic malignancies. Furthermore, though almost all trials report some race information, FDA guidelines are not universally followed. There is a disproportionate disease burden of lung cancer in under-represented race communities, and clinical trials should prioritize racial diversity and inclusion efforts.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias Torácicas
/
Aprobación de Drogas
Tipo de estudio:
Guideline
Límite:
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Cancer Invest
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos